Stockreport

Delcath adds six sites to study of Melphalan/HDS in ocular melanoma; shares ahead 2% [Seeking Alpha]

Delcath Systems, Inc.  (DCTH) 
US:NASDAQ Investor Relations: delcath.com/investors
PDF Delcath adds six sites to study of Melphalan/HDS in ocular melanoma; shares ahead 2% [Read more]